Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$S Argus Reaffirms Hold On Sprint Following CEO’s Remarks At Investor Conference http://www.smarteranalyst.com/2014/09/16/argus-reaffirms-hold-on-sprint-following-ceos-remarks-at-investor-conference/
$S Argus Reaffirms Hold On Sprint Following CEO’s Remarks At Investor Conference http://www.smarteranalyst.com/2014/09/16/argus-reaffirms-hold-on-sprint-following-ceos-remarks-at-investor-conference/
$UTHR H.C. Wainwright Reiterates Buy On United Therapeutics Following Healthcare Conference http://www.smarteranalyst.com/2014/09/15/h-c-wainwright-reiterates-buy-on-united-therapeutics-following-healthcare-conference/
$NPSP Janney Reiterates Buy On NPS Pharmaceuticals As FDA Panel Backs Natpara Approval http://www.smarteranalyst.com/2014/09/15/janney-reiterates-buy-on-nps-pharmaceuticals-as-fda-panel-backs-natpara-approval/
$NPSP Janney Reiterates Buy On NPS Pharmaceuticals As FDA Panel Backs Natpara Approval http://www.smarteranalyst.com/2014/09/15/janney-reiterates-buy-on-nps-pharmaceuticals-as-fda-panel-backs-natpara-approval/
$OHRP Brean Capital Maintains Buy On OHR Pharmaceutical Following Retinal Society Meeting http://www.smarteranalyst.com/2014/09/15/brean-capital-maintains-buy-on-ohr-pharmaceutical-following-retinal-society-meeting/
$ANIP Roth Capital Reiterates Buy On ANI Pharmaceuticals As Shares Have Come Under Pressure http://www.smarteranalyst.com/2014/09/15/roth-capital-reiterates-buy-on-ani-pharmaceuticals-as-shares-have-come-under-pressure/
$ANIP Roth Capital Reiterates Buy On ANI Pharmaceuticals As Shares Have Come Under Pressure http://www.smarteranalyst.com/2014/09/15/roth-capital-reiterates-buy-on-ani-pharmaceuticals-as-shares-have-come-under-pressure/
$ADHD Roth Capital Provides Input Into Alcobra’s Fragile X Program; Keeps $40 Price Target http://www.smarteranalyst.com/2014/09/15/roth-capital-provides-input-into-alcobras-fragile-x-program-keeps-40-price-target/
$ADHD Roth Capital Provides Input Into Alcobra’s Fragile X Program; Keeps $40 Price Target http://www.smarteranalyst.com/2014/09/15/roth-capital-provides-input-into-alcobras-fragile-x-program-keeps-40-price-target/
$ACUR Roth Capital Remains Bullish On Acura Following Submission Of Dispute Resolution Request To FDA http://www.smarteranalyst.com/2014/09/15/roth-capital-remains-bullish-on-acura-following-submission-of-dispute-resolution-request-to-fda/
$ACUR Roth Capital Remains Bullish On Acura Following Submission Of Dispute Resolution Request To FDA http://www.smarteranalyst.com/2014/09/15/roth-capital-remains-bullish-on-acura-following-submission-of-dispute-resolution-request-to-fda/
$NPSP Brean Capital Reiterates Buy On NPS Pharmaceuticals On The Back Of FDA Panel Outcome http://www.smarteranalyst.com/2014/09/15/brean-capital-reiterates-buy-on-nps-pharmaceuticals-on-the-back-of-fda-panel-outcome/
$TGTX Brean Capital Maintains Buy On TG Therapeutics On The Heels Of SPA Agreement http://www.smarteranalyst.com/2014/09/15/brean-capital-maintains-buy-on-tg-therapeutics-on-the-heels-of-spa-with-the-fda/
$TGTX Brean Capital Maintains Buy On TG Therapeutics On The Heels Of SPA Agreement http://www.smarteranalyst.com/2014/09/15/brean-capital-maintains-buy-on-tg-therapeutics-on-the-heels-of-spa-with-the-fda/
$ONTY Cowen Remains Positive On Oncothyreon Despite Clinical Development Termination By Merck KGaA http://www.smarteranalyst.com/2014/09/12/cowen-remains-positive-on-oncothyreon-despite-clinical-development-termination-by-merck-kgaa/
$ONTY Cowen Remains Positive On Oncothyreon Despite Clinical Development Termination By Merck KGaA http://www.smarteranalyst.com/2014/09/12/cowen-remains-positive-on-oncothyreon-despite-clinical-development-termination-by-merck-kgaa/
$PCYC Roth Capital Reiterates Bullish Stance On Pharmacyclics Following New Contract Award http://www.smarteranalyst.com/2014/09/12/roth-capital-reiterates-bullish-stance-on-pharmacyclics-following-new-contract-award/
$PCYC Roth Capital Reiterates Bullish Stance On Pharmacyclics Following New Contract Award http://www.smarteranalyst.com/2014/09/12/roth-capital-reiterates-bullish-stance-on-pharmacyclics-following-new-contract-award/
$EBAY Cantor Maintains Buy On Ebay Despite Fears That “Apple Pay” May Weigh On PayPal http://www.smarteranalyst.com/2014/09/12/cantor-fitzgerald-sticks-with-buy-on-ebay-despite-apple-pay-entering-the-market/
$EBAY Cantor Maintains Buy On Ebay Despite Fears That “Apple Pay” May Weigh On PayPal http://www.smarteranalyst.com/2014/09/12/cantor-fitzgerald-sticks-with-buy-on-ebay-despite-apple-pay-entering-the-market/
$CNVR Cantor Fitzgerald Reaffirms Hold On Conversant Following Acquisition By Alliance Data http://www.smarteranalyst.com/2014/09/12/cantor-fitzgerald-reaffirms-hold-on-conversant-following-acquisition-by-alliance-data/
$NPSP Janney Capital Reiterates Buy On NPS Pharma Ahead Of FDA Meeting For Natpara http://www.smarteranalyst.com/2014/09/12/janney-capital-reiterates-buy-on-nps-pharma-ahead-of-meeting-with-the-fda-for-natpara/
$SYN Maxim Reaffirms Buy On Synthetic Bio Ahead Of Trimesta Presentation http://www.smarteranalyst.com/2014/09/12/maxim-reaffirms-buy-on-synthetic-bio-ahead-of-trimesta-presentation/
$LULU Lululemon: We See No Reason To Step In At This Point, Says Sterne Agee http://www.smarteranalyst.com/2014/09/12/lululemon-we-see-no-reason-to-step-in-at-this-point-says-sterne-agee/
$LULU Lululemon: We See No Reason To Step In At This Point, Says Sterne Agee http://www.smarteranalyst.com/2014/09/12/lululemon-we-see-no-reason-to-step-in-at-this-point-says-sterne-agee/
$TSL Trina Solar: The Optimism On The Back Of Bloomberg’s Article Is Completely Mis-Guided, Says Axiom http://www.smarteranalyst.com/2014/09/12/trina-solar-the-optimism-on-the-back-of-bloombergs-article-is-completely-mis-guided-says-axiom/
$RXII RXi Pharmaceuticals: A Nearly 40% Sell-Off Creates A Unique Buying Opportunity, Says H.C. Wainwright http://www.smarteranalyst.com/2014/09/12/rxi-pharmaceuticals-a-nearly-40-sell-off-creates-a-unique-buying-opportunity-says-h-c-wainwright/
$SPPI H.C. Wainwright Reiterates Buy On Spectrum On The Heels Of Phase 3 Plans For SPI-2012 http://www.smarteranalyst.com/2014/09/12/h-c-wainwright-reiterates-buy-on-spectrum-on-the-heels-of-phase-3-plans-for-spi-2012/
$SPPI H.C. Wainwright Reiterates Buy On Spectrum On The Heels Of Phase 3 Plans For SPI-2012 http://www.smarteranalyst.com/2014/09/12/h-c-wainwright-reiterates-buy-on-spectrum-on-the-heels-of-phase-3-plans-for-spi-2012/
$KERX Keryx: Brean Capital Provides Key Takeaways From Investor Meeting With Management http://www.smarteranalyst.com/2014/09/12/keryx-brean-capital-provides-key-takeaways-from-investor-meeting-with-management/
$KERX Keryx: Brean Capital Provides Key Takeaways From Investor Meeting With Management http://www.smarteranalyst.com/2014/09/12/keryx-brean-capital-provides-key-takeaways-from-investor-meeting-with-management/
$KERX Roth Capital Reiterates Buy On Keryx As All Eyes On Zerenex Approval Decision; Sees 95% Chance Of Success http://www.smarteranalyst.com/2014/09/02/roth-capital-reiterates-buy-on-keryx-as-all-eyes-are-on-zerenex-approval-decision-sees-95-chance-of-success/
$KERX Roth Capital Reiterates Buy On Keryx As All Eyes On Zerenex Approval Decision; Sees 95% Chance Of Success http://www.smarteranalyst.com/2014/09/02/roth-capital-reiterates-buy-on-keryx-as-all-eyes-are-on-zerenex-approval-decision-sees-95-chance-of-success/
We Believe UnitedHealth Is Entering 2015 Positioned Strongly, Says Wedbush http://www.smarteranalyst.com/2014/08/29/we-believe-unitedhealth-is-entering-2015-positioned-strongly-says-wedbush/
$UTHR Cowen Maintains Bullish Stance On United Therapeutics Following Victory In Remodulin Legal Fight http://www.smarteranalyst.com/2014/08/29/cowen-maintains-bullish-stance-on-united-therapeutics-following-victory-in-remodulin-legal-fight/
$UTHR Cowen Maintains Bullish Stance On United Therapeutics Following Victory In Remodulin Legal Fight http://www.smarteranalyst.com/2014/08/29/cowen-maintains-bullish-stance-on-united-therapeutics-following-victory-in-remodulin-legal-fight/
$ANF Abercrombie: We Believe The Stock Offers Value For LT Investors, Says William Blair http://www.smarteranalyst.com/2014/08/29/abercrombie-we-believe-the-stock-offers-value-for-lt-investors-says-william-blair/
$ANF Abercrombie: We Believe The Stock Offers Value For LT Investors, Says William Blair http://www.smarteranalyst.com/2014/08/29/abercrombie-we-believe-the-stock-offers-value-for-lt-investors-says-william-blair/
$WSM Williams-Sonoma: William Blair Analyst Recommends Investors To Establish Or Add To Positions On This Pullback http://www.smarteranalyst.com/2014/08/29/williams-sonoma-william-blair-recommends-investors-to-establish-or-add-to-positions-on-this-pullback/